Wegrow
Hans-Peter Frank is an accomplished executive with extensive experience in the biotech and healthcare sectors. Currently serving as Global Industrial Partnerships Executive Advisor at NEOM, Hans-Peter is instrumental in realizing the ambitious vision for a comprehensive health and biotech ecosystem. Alongside this role, Hans-Peter is a Member of the Municipal Council for Gemeinde Bottighofen, Chair of the Board of Directors at Alex Therapeutics, and a Global Business Development Manager at Wegrow. Additional positions include Life Science Relationship Executive at machineMD, Global Tendering & Pricing Excellence Senior Executive at Cube RM, and a member of various advisory boards, including TOM Medications and DigitalHealth.London. With a robust academic background that includes multiple degrees focused on economics, law, innovation management, and engineering from renowned institutions such as Harvard Business School and Delft University of Technology, Hans-Peter combines expertise in business strategy and healthcare innovation to drive growth and development within the industry.
This person is not in any offices
Wegrow
3 followers
We want to be the leading digital platform for organizations to efficiently share and implement best practices, resulting in improved collaboration and increased profitability. Our mission is to transform the way companies approach sharing and scaling best practices. We believe that by empowering teams to easily share their knowledge and experience, we can help drive ROI and margin growth. We want to make the process engaging and even fun, so that people are motivated to participate and contribute their insights. By doing so, we can help businesses unlock the full potential of their teams and drive lasting success. Drive measurable results. Central teams often spend a lot of time, effort, and money organizing knowledge sharing between markets, without dedicated and efficient tools. Meanwhile, local teams spend too much time searching for proven initiatives to replicate and end up reinventing the wheel on their side. This ultimately results in financial loss and criticism towards central teams.